Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity

Autoimmunity Reviews

Volumn 13, Issue 9, 2014, Pages 974-980

  Lanteri, Aurélia ^a,b   Sobanski, Vincent ^a,b   Langlois, Carole ^a,b   Lefèvre, Guillaume ^a,b   Hauspie, Carine ^a,b   Sanges, Sébastien ^a,b   Lambert, Marc ^a,b   Morell Dubois, Sandrine ^a,b   Hatron, Pierre Yves ^a,b   Hachulla, Eric ^a,b   Launay, David ^a,b   Dubucquoi, Sylvain ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

B cells; BAFF; Beta2 microglobulin; Free light chain; Systemic sclerosis

Indexed keywords

B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; BIOLOGICAL MARKER;

ADULT; ANTIBODY TITER; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY ASSESSMENT; EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDSGER TOTAL SEVERITY SCORE; MIDDLE AGED; MODIFIED RODNAN SKIN SCORE; MONOCLONAL IMMUNOGLOBULINEMIA; PROSPECTIVE STUDY; PROTEIN FUNCTION; REVIEW; SCORING SYSTEM; SYSTEMIC SCLEROSIS; B LYMPHOCYTE; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; SEVERITY OF ILLNESS INDEX;

B-LYMPHOCYTES; BIOLOGICAL MARKERS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LUNG; LYMPHOCYTE ACTIVATION; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 84922606187     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.07.003     Document Type: Review

References (46)

1. Hachulla E., Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011, 40:78-83.
2. Jimenez S.A., Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjogren's syndrome. Autoimmun Rev 2013, 12:1046-1051.
3. Careta M.F., Leite Cda C., Cresta F., et al. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face. Autoimmun Rev 2013, 12:1064-1069.
4. Almeida I., Faria R., Vita P., et al. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev 2011, 10:693-701.
5. Abignano G., Cuomo G., Buch M.H., et al. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis 2014, 73:420-427.
6. Moinzadeh P., Denton C.P., Abraham D., et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 2012, 26:267-276.
7. Chizzolini C., Brembilla N.C., Montanari E., et al. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011, 10:276-281.
8. Van Praet J.T., Van Steendam K., Smith V., et al. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. Rheumatology (Oxford) 2011, 50:1302-1309.
9. Sobanski V., Dauchet L., Lefevre G., et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 2014, 66:407-417.
10. Hasegawa M., Fujimoto M., Takehara K., et al. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005, 39:1-7.
11. Hasegawa M. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010, 37:3-10.
12. Giuggioli D., Manfredi A., Colaci M., et al. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12:1058-1063.
13. Elhai M., Avouac J., Kahan A., et al. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013, 12:1052-1057.
14. Komura K., Yanaba K., Ogawa F., et al. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody. Clin Exp Dermatol 2008, 33:329-332.
15. Yuhara T., Takemura H., Akama T., et al. The relationship between serum immunoglobulin levels and pulmonary involvement in systemic sclerosis. J Rheumatol 2000, 27:1207-1214.
16. Sato S., Fujimoto M., Hasegawa M., et al. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927.
17. Francois A., Chatelus E., Wachsmann D., et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013, 15:R168.
18. Mackay F., Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
19. Matsushita T., Hasegawa M., Yanaba K., et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
20. Daoussis D., Liossis S.N., Yiannopoulos G., et al. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011, 2011:214013.
21. Smith V., Van Praet J.T., Vandooren B., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197.
22. Zandman-Goddard G., Tweezer-Zaks N., Shoenfeld Y. New therapeutic strategies for systemic sclerosis-a critical analysis of the literature. Clin Dev Immunol 2005, 12:165-173.
23. Bosello S., De Luca G., Tolusso B., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011, 10:624-630.
24. Hopper J.E., Papagiannes E. Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell Immunol 1986, 101:122-131.
25. Faint J.M., Basu S., Sutton D., et al. Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay. Clin Chem Lab Med 2014, [in press]. 10.1515/cclm-2014-0279.
26. Larsen J.T., Kumar S.K., Dispenzieri A., et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013, 27:941-946.
27. Jolly M., Francis S., Aggarwal R., et al. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus 2014, 23:881-888.
28. Gottenberg J.E., Aucouturier F., Goetz J., et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007, 66:23-27.
29. Gottenberg J.E., Seror R., Miceli-Richard C., et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013, 8:e59868.
30. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590.
31. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
32. Hervier B., Devilliers H., Stanciu R., et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012, 12:210-217.
33. Lega J.-C., Fabien N., Reynaud Q., et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014, 13:883-891.
34. Valentini G., Della Rossa A., Bombardieri S., et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001, 60:592-598.
35. Medsger T.A., Bombardieri S., Czirjak L., et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21:S42-S46.
36. Silver R.M., Metcalf J.F., LeRoy E.C. Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum 1986, 29:525-531.
37. Harrison N.K., Myers A.R., Corrin B., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991, 144:706-713.
38. Martinez-Cordero E., Trejo A.P., Leon D.E. IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis. J Clin Lab Anal 2009, 23:408-416.
39. Volpe A., Ruzzenente O., Caramaschi P., et al. Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 2009, 29:1073-1079.
40. Jonsson T., Valdimarsson H. What about IgA rheumatoid factor in rheumatoid arthritis?. Ann Rheum Dis 1998, 57:63-64.
41. Matsushita T., Hasegawa M., Matsushita Y., et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007, 16:87-93.
42. Kraneveld A.D., Kool M., van Houwelingen A.H., et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci U S A 2005, 102:1578-1583.
43. Hugle T., White K., van Laar J.M. Cell-to-cell contact of activated mast cells with fibroblasts and lymphocytes in systemic sclerosis. Ann Rheum Dis 2012, 71:1582.
44. Chanez P., Lacoste J.Y., Guillot B., et al. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung. Am Rev Respir Dis 1993, 147:1497-1502.
45. Aggarwal R., Sequeira W., Kokebie R., et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken) 2011, 63:891-898.
46. Tate J., Bazeley S., Sykes S., et al. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009, 30:131-140.